Momenta revises regulatory strategy for proposed Humira biosimilar

This article was originally published here

Momenta had previously guided that it planned to file a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) in the fourth quarter of this

The post Momenta revises regulatory strategy for proposed Humira biosimilar appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply